Baricitinib, a known inhibitor of JAK1 and JAK2 signaling, has been previously reported to ameliorate several hallmarks of cellular aging in both normal and Hutchinson–Gilford Progeria Syndrome (HGPS) cells [19,20]. The gene discussed is JAK2; the disease is Hutchinson-Gilford progeria syndrome.